शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
FABTECHNSEFabtech Technologies Limited· Healthcare Equipment & SuppliesMediumNeutral
Announced Fri, 14 Nov, 2025 · 11:35 IST

Fabtech Technologies shares H1 FY26 earnings call transcript; revenue up 110%

Order pipeline disclosedManagement guided margin improvementInvestor Communications View source PDFExplain this filing

FABTECH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+6.9%Reaction day
₹231.16
prior close
₹243.75
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+6.9% vs market
Medical Equipment & Supplies peers, median of 13sector-0.4%+7.3% vs sector

On the reaction day the stock moved 6.9 pts more than Nifty Microcap 250 and 7.3 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.2
10m
+0.0
15m
+0.1
30m
+0.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+6.9-0.1+6.9-0.4+7.3
Next day
+7.9+0.5+7.4-2.0+9.9
2d
+3.8-0.3+4.1-3.2+7.1
3d
+3.0-0.5+3.4-4.0+7.0
4d
+3.8-0.8+4.6-4.3+8.1
5d
+3.2-2.3+5.5-5.8+8.9
1w
+4.4-2.8+7.2-7.2+11.6
15d
+5.7-4.9+10.5-4.2+9.9
1m
-1.8-4.7+2.9-4.3+2.5
2m
-18.8-7.7-11.0-10.4-8.4
3m
-30.2-7.8-22.4-11.6-18.7
UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fabtech Technologies reported H1 FY26 total income of INR19,322.80 lakhs, up 109.9% YoY, with net profit of INR2,198.02 lakhs, up 101.6%. EBITDA stood at INR2,839.99 lakhs with margins at 14.7%. Order book was INR90,441.87 lakhs as of July 2025, growing 7-9% by September. The company operates in 22 countries, focused on pharma turnkey projects in MENA and GCC regions. Management targets 20-25% sustained yearly growth but declined specific margin guidance, calling it a lumpy project business. An MOU with KP Group for sustainable energy was also disclosed.

Likely market impact

Strong H1 with doubled revenue and profits. Order book provides growth visibility, but management evaded margin guidance, leaving investors to model on yearly trends.